Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer

• Verfasst von: Kast, Karin [VerfasserIn]
• Verfasst von: Fischer, Christine [VerfasserIn]
• Verfasst von: Dikow, Nicola [VerfasserIn]
• Verfasst von: Schott, Sarah [VerfasserIn]
• Titel: Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer
• Verf.angabe: Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle, Michael Braun, Christine Fischer, Nicola Dikow, Sarah Schott, Nils Rahner, Dieter Niederacher, Tanja Fehm, Andrea Gehrig, Clemens Mueller-Reible, Norbert Arnold, Nicolai Maass, Guntram Borck, Nikolaus de Gregorio, Caroline Scholz, Bernd Auber, Raymonda Varon-Manteeva, Dorothee Speiser, Judit Horvath, Nadine Lichey, Pauline Wimberger, Sylvia Stark, Ulrike Faust, Bernhard H. F. Weber, Gunter Emons, Silke Zachariae, Alfons Meindl, Rita K. Schmutzler, Christoph Engel, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)
• E-Jahr: 2016
• Jahr: 29 February 2016
• Umfang: 7 S.
• Fussnoten: Gesehen am 12.03.2018
• Titel Quelle: Enthalten in: Journal of medical genetics
• Ort Quelle: London : BMJ Publishing Group, 1964
• Jahr Quelle: 2016
• Band/Heft Quelle: 53(2016), 7, Seite 465-471
• ISSN Quelle: 1468-6244
• DOI: doi:10.1136/jmedgenet-2015-103672
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: BRCA1
• Sach-SW: BRCA2
• Sach-SW: Mutation prevalences
• Sach-SW: risk criteria
• K10plus-PPN: 1570920060

Abstract

Purpose To characterise the prevalence of pathogenic germline mutations in BRCA1 and BRCA2 in families with breast cancer (BC) and ovarian cancer (OC) history. Patients and methods Data from 21 401 families were gathered between 1996 and 2014 in a clinical setting in the German Consortium for Hereditary Breast and Ovarian Cancer, comprising full pedigrees with cancer status of all individual members at the time of first counselling, and BRCA1/2 mutation status of the index patient. Results The overall BRCA1/2 mutation prevalence was 24.0% (95% CI 23.4% to 24.6%). Highest mutation frequencies were observed in families with at least two OCs (41.9%, 95% CI 36.1% to 48.0%) and families with at least one breast and one OC (41.6%, 95% CI 40.3% to 43.0%), followed by male BC with at least one female BC or OC (35.8%; 95% CI 32.2% to 39.6%). In families with a single case of early BC (<36 years), mutations were found in 13.7% (95% CI 11.9% to 15.7%). Postmenopausal unilateral or bilateral BC did not increase the probability of mutation detection. Occurrence of premenopausal BC and OC in the same woman led to higher mutation frequencies compared with the occurrence of these two cancers in different individuals (49.0%; 95% CI 41.0% to 57.0% vs 31.5%; 95% CI 28.0% to 35.2%). Conclusions Our data provide guidance for healthcare professionals and decision-makers to identify individuals who should undergo genetic testing for hereditary breast and ovarian cancer. Moreover, it supports informed decision-making of counselees on the uptake of genetic testing.